Accellix develops and commercializes the Accellix Platform, a benchtop flow cytometer that reads capillary cartridges integrated with dry reagents to deliver quick, accurate flow cytometry results at the point-of-need. The system is designed for use by cell therapy companies on the manufacturing floor to streamline complex cell analysis and routine QC. Accellix says its products provide reproducible, automated multi-parametric cell analysis while reducing overall QC costs. The company reports it grew its customer base 10X over the past two years, with some customers already implementing the Accellix Platform in commercial GMP manufacturing processes. Management plans to accelerate commercial and development efforts and invest in the infrastructure required to support customer needs. The recent financing provides additional capital to support those plans. Accellix develops and commercializes the Accellix platform, a benchtop cytometer that reads capillary cartridges integrated with dry reagents for automated multi-parametric cell analysis. The platform automates complex flow cytometry processes into a sample-to-answer system that provides immediate results at the point of need and reduces the requirement to send samples to central labs. Accellix targets cell and gene therapy quality control workflows and helps customers migrate existing cell assays to its platform, aiming to replace costly and complicated flow cytometry procedures. The company has operations in San Jose, Calif., and Jerusalem. Financially, Accellix announced a $9.5 million Series D led by bioMérieux and converted $8.5 million of pre-existing convertible notes from existing investors, bringing this round's total to $18 million. The funding will be used to expand the Accellix system's market reach and to strengthen service and support capabilities for customers developing cellular therapies.

Total raised

$20M

Funding rounds

2

Latest round

Equity

Latest activity

Dec 2021